TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07735637: A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus

Sponsor: AstraZeneca · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 750 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$16,532,208

Rescue Site Savings

+$10,890,264

Unlock Full NCT07735637 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07735637 Rescue Dossier →